IMARC Group’s latest research report, titled “Renal Biomarkers Market: Global Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2022-2027,” offers a detailed analysis of the market drivers, segmentation, growth opportunities, trends, and competitive landscape to understand the current and future market scenarios.
The global renal biomarkers market size reached US$ 1.13 Billion in 2021. Looking forward, IMARC Group expects the market to reach a value of US$ 1.88 Billion by 2027, exhibiting a CAGR of 8.70% during 2022-2027.
Renal biomarkers refer to proteins, liquids, microRNAs, metabolites, genes, lipids, or proteomic patterns on a urinalysis. These patterns aid in ascertaining the glomerular filtration rate (GFR) of the kidney to determine its proper functioning and evaluate pathogenic procedures or pharmacological responses to therapeutic interventions. In recent years, renal biomarkers have gained traction in hospital and diagnostic laboratories across the globe due to their ability to predict disease progression and compute drug dosage.
Get Free Sample Copy of Report at – https://www.imarcgroup.com/renal-biomarkers-market/requestsample
Important Attribute and highlights of the Report:
Detailed analysis of the global market share
Market Segmentation by type, diagnostic technique, end user and region.
Historical, current, and projected size of the market in terms of volume and value
Latest industry trends and developments
Competitive Landscape for Renal Biomarkers Market
Strategies of major players and product offerings
One of the primary factors driving the market is the rising prevalence of individuals diagnosed with chronic kidney disease (CKD) and non-communicable diseases with considerable mortality and morbidity. Additionally, renal biomarkers, along with serum creatinine (SCr), blood urea nitrogen (BUN), urinary albumin or protein, and volume excretion, are extensively utilized to diagnose and monitor chronic kidney disease (CKD). Besides this, there is widespread adoption of novel biomarkers and process-specific biomarker panels as they share prognostic and diagnostic information and assist in predicting the response to the treatment of glomerulopathies, autosomal dominant polycystic kidney disease (ADPKD), and acute kidney injury. Other major growth-inducing factors include the accessibility and feasibility of this product in all-sized laboratories, development and integration of epigenetics, transcriptomics, metabolomics, proteomics and genomics, growing healthcare industry, increasing geriatric population, and rising number of clinical trials for CKD globally.
Key Players Included in Global Research Report:
• Abbott Laboratories
• Beckman Coulter Inc. (Danaher Corporation)
• bioMérieux SA
• BioPorto A/S
• Bio-Rad Laboratories Inc.
• Enzo Biochem Inc.
• F. Hoffmann-La Roche AG
• PerkinElmer Inc.
• Randox Laboratories Ltd.
• Siemens AG
• Thermo Fisher Scientific Inc.
Ask Analyst for Customization and Explore Full Report with TOC & List of Figure: https://www.imarcgroup.com/request?type=report&id=5273&flag=C
COVID-19 Impact Overview:
We are regularly tracking the direct effect of COVID-19 on the market, along with the indirect influence of associated industries. These observations will be integrated into the report.
Breakup by Type:
• Functional Biomarker
o Serum Creatinine
o Serum Cystatin C
o Urine Albumin
• Up-regulated Protein
o Neutrophil Gelatinase-Associated Lipocalin (NGAL)
o Kidney Injury Molecule-1
Breakup by Diagnostic Technique:
• Enzyme-linked Immunosorbent Assay (ELISA)
• Particle-enhanced Turbidimetric Immunoassay (PETIA)
• Colorimetric Assay
• Chemiluminescent Enzyme Immunoassay (CLIA)
• Liquid Chromatography Mass Spectrometry (LC-MS)
Breakup by End User:
• Diagnostic Laboratory
Breakup by Region:
• North America: (United States, Canada)
• Asia Pacific: (China, Japan, India, South Korea, Australia, Indonesia, Others)
• Europe: (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
• Latin America: (Brazil, Mexico, Others)
• Middle East and Africa
TOC for the Renal Biomarkers Market Research Report:
• Scope and Methodology
• Executive Summary
• Global Renal Biomarkers Market
• SWOT Analysis
• Value Chain Analysis
• Price Analysis
• Competitive Landscape
Who we are:
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
30 N Gould St, Ste R
Sheridan, WY (Wyoming) 82801 USA
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800